Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib in Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic Alterations
NCT02365597Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2015
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of erdafitinib in urothelial carcinoma (UC), sponsored by Janssen Pharmaceutical. Started Apr 2015; status: active, not recruiting.
02
Drugs
erdafitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02365597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365597.